Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients

dc.contributor.authorel-Hajj, Stephanie C.
dc.contributor.authorAlJaroudi, Wael A.
dc.contributor.authorFarag, Ayman A.
dc.contributor.authorBleich, Steven
dc.contributor.authorManaoragada, Padma
dc.contributor.authorIskandrian, Ami E.
dc.contributor.authorHage, Fadi G.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentCardiology Services
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:48:05Z
dc.date.available2025-01-24T11:48:05Z
dc.date.issued2016
dc.description.abstractBackground: The prognostic value of single-photon emission computed tomography myocardial perfusion imaging (MPI) is well established. There is a paucity of data on the prognostic value of changes in perfusion defect size (PDS) on serial MPIs. Methods: From the MPI database at the University of Alabama at Birmingham, consecutive patients who underwent two regadenoson stress MPIs between July 2008 and March 2013 were identified. The MPIs were analyzed side-by-side using an automated software program for presence and change in PDS. Improvement in PDS was defined as a reduction ≥5% of left ventricle. A drop in left ventricular ejection fraction (LVEF) was defined as a decrease ≥5%. The primary outcome was a composite of death, myocardial infarction (MI), and coronary revascularization (CR). Results: There were 698 patients (61 ± 11 years, 53% male, 48% diabetes, 25% prior MI, 49% prior CR) who underwent two regadenoson MPIs within 16 ± 9 months for clinical indications. The primary outcome occurred in 167 (24%) patients (8% death, 9% MI, 15% CR) during 24 ± 16 months of follow-up after the second MPI. The MPIs were normal in both studies in 399 (57%, Group 1), showed improvement in 94 (14%, Group 2, PDS 15% ± 16% vs 28% ± 18%, P < .001) and no change or worsening in 205 patients (29%, Group 3, 28% ± 17% vs 20% ± 17%, P < .001). The best outcomes were seen in Group 1 and the worst in Group 3 (log-rank P < .001). Similar trends were seen for the components of the primary outcome (P = .04 for death, P < .001 for MI, P < .001 for CR). In a Cox-regression model that adjusted for baseline factors including PDS and LVEF on initial MPI, the hazard ratios for primary outcome were 2.0 (P = .02) and 3.9 (P < .001) for Groups 2 and 3 compared to Group 1, respectively. In addition, an LVEF drop ≥5% was independently associated with the primary outcome (HR 1.5, P = .01). Conclusion: Changes in PDS and LVEF on serial MPIs provide incremental prognostic information to initial and follow-up MPI findings. Lack of improvement or an increase in PDS and a drop in LVEF identify high-risk patients. © 2015, American Society of Nuclear Cardiology.
dc.identifier.doihttps://doi.org/10.1007/s12350-015-0174-8
dc.identifier.eid2-s2.0-84955216050
dc.identifier.pmid26017713
dc.identifier.urihttp://hdl.handle.net/10938/30790
dc.language.isoen
dc.publisherSpringer New York LLC
dc.relation.ispartofJournal of Nuclear Cardiology
dc.sourceScopus
dc.subjectMyocardial perfusion imaging
dc.subjectOutcomes
dc.subjectRegadenoson
dc.subjectSerial
dc.subjectAlabama
dc.subjectComorbidity
dc.subjectContrast media
dc.subjectCoronary artery disease
dc.subjectExercise test
dc.subjectFemale
dc.subjectHumans
dc.subjectImage interpretation, computer-assisted
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMyocardial infarction
dc.subjectPercutaneous coronary intervention
dc.subjectPrevalence
dc.subjectPrognosis
dc.subjectPurines
dc.subjectPyrazoles
dc.subjectReproducibility of results
dc.subjectRisk assessment
dc.subjectSensitivity and specificity
dc.subjectSurvival rate
dc.subjectVasodilator agents
dc.subjectContrast medium
dc.subjectPurine derivative
dc.subjectPyrazole derivative
dc.subjectVasodilator agent
dc.subjectAdult
dc.subjectArticle
dc.subjectDeath
dc.subjectFollow up
dc.subjectHeart infarction
dc.subjectHeart left ventricle ejection fraction
dc.subjectHeart muscle perfusion
dc.subjectHeart muscle revascularization
dc.subjectHuman
dc.subjectMajor clinical study
dc.subjectPerfusion defect size
dc.subjectPriority journal
dc.subjectComputer assisted diagnosis
dc.subjectDiagnostic imaging
dc.subjectEpidemiology
dc.subjectMortality
dc.subjectProcedures
dc.subjectReproducibility
dc.subjectStatistics and numerical data
dc.titleEffect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2016-9638.pdf
Size:
983.18 KB
Format:
Adobe Portable Document Format